Header Logo

Connection

Peter Friedmann to Naltrexone

Back to Details
This is a "connection" page, showing publications Peter Friedmann has written about Naltrexone.
Peter Friedmann
Connection Strength
5.547
Naltrexone
  1. Soares WE, Wilson D, Gordon MS, Lee JD, Nunes EV, O'Brien CP, Shroff M, Friedmann PD. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. Drug Alcohol Depend. 2019 01 01; 194:482-486.
    View in: PubMed
    Score: 0.574
  2. Abraham AJ, Andrews CM, Grogan CM, Pollack HA, D'Aunno T, Humphreys K, Friedmann PD. State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder. Psychiatr Serv. 2018 04 01; 69(4):448-455.
    View in: PubMed
    Score: 0.537
  3. Friedmann PD, Dunn KE, Nunes EV, O'Brien CP. Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT. J Subst Abuse Treat. 2018 02; 85:31-33.
    View in: PubMed
    Score: 0.535
  4. Soares WE, Wilson D, Rathlev N, Lee JD, Gordon M, Nunes EV, O'Brien CP, Friedmann PD. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. J Subst Abuse Treat. 2018 02; 85:66-69.
    View in: PubMed
    Score: 0.515
  5. Friedmann PD, Wilson D, Hoskinson R, Poshkus M, Clarke JG. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison. J Subst Abuse Treat. 2018 02; 85:45-48.
    View in: PubMed
    Score: 0.513
  6. Friedmann PD, Wilson D, Nunes EV, Hoskinson R, Lee JD, Gordon M, Murphy SM, Bonnie RJ, Chen DT, Boney TY, O'Brien CP. Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? J Subst Abuse Treat. 2018 02; 85:61-65.
    View in: PubMed
    Score: 0.508
  7. Friedmann PD, Mello D, Lonergan S, Bourgault C, O'Toole TP. Aversion to injection limits acceptability of extended-release naltrexone among homeless, alcohol-dependent patients. Subst Abus. 2013; 34(2):94-6.
    View in: PubMed
    Score: 0.381
  8. Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T, Knight K, Flynn PM, Welsh WN, Stein LA, Sacks S, O'Connell DJ, Knudsen HK, Shafer MS, Hall E, Frisman LK. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012; 33(1):9-18.
    View in: PubMed
    Score: 0.355
  9. Friedmann PD, Wilson D, Stopka TJ, Bernson D, Pivovarova E, Ferguson W, Hoskinson RA, Rottapel RE, Bovell-Ammon B, Gaba A, Morgan JR, Senst T, Hayes E, Evans EA. Medications for Opioid Use Disorder in County Jails - Outcomes after Release. N Engl J Med. 2025 Sep 11; 393(10):994-1003.
    View in: PubMed
    Score: 0.230
  10. Pivovarova E, Min HS, Friedmann PD. Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders. Subst Abus. 2021; 42(4):618-624.
    View in: PubMed
    Score: 0.162
  11. Chen DT, Ko TM, Allen AA, Bonnie RJ, Suratt CE, Appelbaum PS, Nunes EV, Friedmann PD, Lee JD, Gordon MS, McDonald R, Wilson D, Boney TY, Murphy SM, O'Brien CP. Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision. J Empir Res Hum Res Ethics. 2018 04; 13(2):160-172.
    View in: PubMed
    Score: 0.136
  12. Friedmann PD, Suzuki J. More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic. Addict Sci Clin Pract. 2017 11 15; 12(1):29.
    View in: PubMed
    Score: 0.133
  13. Allen AA, Chen DT, Bonnie RJ, Ko TM, Suratt CE, Lee JD, Friedmann PD, Gordon M, McDonald R, Murphy SM, Boney TY, Nunes EV, O'Brien CP. Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. J Subst Abuse Treat. 2017 10; 81:66-72.
    View in: PubMed
    Score: 0.131
  14. Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, Hu MC, Boney TY, Wilson D, O'Brien CP. Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. J Subst Abuse Treat. 2018 02; 85:49-55.
    View in: PubMed
    Score: 0.128
  15. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016 Mar 31; 374(13):1232-42.
    View in: PubMed
    Score: 0.119
  16. Lee JD, Friedmann PD, Boney TY, Hoskinson RA, McDonald R, Gordon M, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O'Brien CP. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials. 2015 Mar; 41:110-7.
    View in: PubMed
    Score: 0.110
  17. Park TW, Friedmann PD. Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders. R I Med J (2013). 2014 Oct 01; 97(10):20-4.
    View in: PubMed
    Score: 0.108
  18. Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PD, Nunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ES, O'Brien CP. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012; 33(1):48-59.
    View in: PubMed
    Score: 0.089
  19. Ober AJ, Murray-Krezan C, Page K, Friedmann PD, Anderson J, Osilla KC, Ryzewicz S, Huerta S, Mazer MW, Hoskinson RA, Garvey R, Peltz A, Watkins KE, Nuckols T, IsHak WW, Mariano LT, Danovitch I. Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial. JAMA Intern Med. 2025 Jun 01; 185(6):624-633.
    View in: PubMed
    Score: 0.056
  20. Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2025 04 01; 8(4):e255340.
    View in: PubMed
    Score: 0.056
  21. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019. Drug Alcohol Depend. 2024 Sep 01; 262:111392.
    View in: PubMed
    Score: 0.053
  22. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Netw Open. 2024 03 04; 7(3):e242732.
    View in: PubMed
    Score: 0.052
  23. Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, Remien RH, Crystal S, Friedmann PD, Levin FR, Olfson M. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018 08; 91:57-68.
    View in: PubMed
    Score: 0.035
  24. Murphy SM, Polsky D, Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Bonnie RJ, Gordon M, Chen DT, Boney TY, O'Brien CP. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. Addiction. 2017 Aug; 112(8):1440-1450.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.